Shikiar Asset Management’s ADMA Biologics ADMA Stock Holding History

Shikiar Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,150	Closed	-$63K	–	77
2018 Q3	$63K	Buy	+10,150	New	+$58.5K	0.02%	79

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

MWVC

Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Shikiar Asset Management's ADMA Position: Q4 2018 in Review

Shikiar Asset Management sold out of ADMA Biologics (ADMA) in Q4 2018, closing a stake of 10,150 shares — an estimated $63K sold.

Shikiar Asset Management first reported a position in ADMA in Q3 2018 and held it in 1 quarter. The position peaked at $63K in Q3 2018. 52 funds tracked by Wall St. Rank hold ADMA as of Q4 2018.

Shikiar Asset Management reported no remaining ADMA Biologics position as of Q4 2018 after selling out during the quarter.
Shikiar Asset Management sold 10,150 ADMA Biologics shares in Q4 2018, an estimated $63K.
Shikiar Asset Management first reported a position in ADMA Biologics in Q3 2018 and held it in 1 quarter.
Shikiar Asset Management's ADMA Biologics position peaked at $63K in Q3 2018.
52 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2018.

Based on Shikiar Asset Management's 13F filing for Q4 2018, filed 1 Feb 2019.